https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-06-26 / N. Engl. J. Med. 2018 07;379(2):150-161
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-06-26 / N. Engl. J. Med. 2018 07;379(2):150-1612018-06-26 00:00:002019-02-15 09:00:21Recurrent Glioblastoma Treated with Recombinant Poliovirus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-05-29 / Front Immunol 2018;9:727
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-05-29 / Front Immunol 2018;9:7272018-05-29 00:00:002019-02-15 08:47:36Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-05-29 / J Transl Med 2018 May;16(1):142
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-05-29 / J Transl Med 2018 May;16(1):1422018-05-29 00:00:002019-02-15 08:47:35First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-03-08 / Exp Ther Med 2018 May;15(5):4522-4530
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-03-08 / Exp Ther Med 2018 May;15(5):4522-45302018-03-08 00:00:002019-02-15 09:00:23Overexpression of p53 delivered using recombinant NDV induces apoptosis in glioma cells by regulating the apoptotic signaling pathway
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-01-29 / Oncoimmunology 2018;7(4):e1412901
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-01-29 / Oncoimmunology 2018;7(4):e14129012018-01-29 00:00:002019-02-15 08:47:40Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8 T cell activation in the presence of adjuvant temozolomide
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-12-05 / J. Neurol. 2018 Apr;265(4):741-756
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-12-05 / J. Neurol. 2018 Apr;265(4):741-7562017-12-05 00:00:002019-02-15 08:47:38Advances in immunotherapeutic research for glioma therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-11-03 / BMJ Open 2017 Nov;7(11):e017387
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-11-03 / BMJ Open 2017 Nov;7(11):e0173872017-11-03 00:00:002017-11-03 00:00:00Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a two-centre German cohort trial with systematic comparison and effect-to-treatment analysis
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-09-23 / Cancer Lett. 2017 12;411:182-190
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-09-23 / Cancer Lett. 2017 12;411:182-1902017-09-23 00:00:002019-02-15 08:46:13Co-delivery of tumor-derived exosomes with alpha-galactosylceramide on dendritic cell-based immunotherapy for glioblastoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-09-20 / Oncoscience 2017 Jul;4(7-8):67-69
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-09-20 / Oncoscience 2017 Jul;4(7-8):67-692017-09-20 00:00:002019-02-15 08:36:14Curing glioblastoma: oncolytic HSV-IL12 and checkpoint blockade
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-08-14 / Cancer Cell 2017 08;32(2):253-267.e5
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-08-14 / Cancer Cell 2017 08;32(2):253-267.e52017-08-14 00:00:002017-08-14 00:00:00Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade
